| Name | Title | Contact Details |
|---|---|---|
Huafeng Xu |
Chief Technology Officer | Profile |
Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company is focusing on the development of the lead product candidate melflufen, a first-in-class anti-cancer peptide-drug conjugate that rapidly delivers an alkylating payload into tumor cells. Melflufen is in development as a new treatment for the hematological cancer multiple myeloma and is currently being evaluated in multiple clinical studies including the pivotal phase 2 HORIZON study and the ongoing phase 3 OCEAN study. Oncopeptides` headquarters is in Stockholm, Sweden with U.S. headquarters in Boston, Mass. The company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO.
LifeWays is the Community Mental Health Agency for Jackson and Hillsdale Counties. We provide specialty mental health services to individuals with Medicaid or Healthy Michigan, living in Jackson or Hillsdale County. Once someone receives a screenin...
Learn about who we are, our approach to scientific innovation, our areas of therapeutic focus, our products, commitments and more.
At Walgreens, we help people get, stay and live well. That`s our core purpose and the difference we make in people`s lives every day. Our purpose has shaped the direction of our company since Charles R. Walgreen Sr. founded his first drugstore in 1901, and it still does today. Our team members make that purpose come to life in our over 7,800 stores in all 50 states, the District of Columbia and Puerto Rico, in our call centers, distribution centers, on-site clinics, specialty pharmacies and corporate offices. In fact, those daily demonstrations of our purpose have helped Walgreens become an industry leader and a household name. Walgreens has something for everyone who wants to build a successful career. Here, you`ll find supportive co-workers, an innovative environment and the tools you need to grow your skills, help build healthy communities and advance your career.
With over 100 years of combined experience, the seasoned leadership team at Allegro Ophthalmics is dedicated to delivering and establishing Integrin Peptide Therapy TM as the next generation pharmaceutical category for the treatment of wet age-related macular degeneration, diabetic retinopathy and diabetic macular edema. The potential to liberate patients from legal blindness to a much improved quality of life sustained by self-sufficient functional vision propels and accelerates our efforts.